Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and @c-catenin inhibition (Englisch)
- Neue Suche nach: Niu, C. C.
- Neue Suche nach: Zhao, C.
- Neue Suche nach: Zhang, X. L.
- Neue Suche nach: Pan, J.
- Neue Suche nach: Wu, W. R.
- Neue Suche nach: Li, Z. Q.
- Neue Suche nach: Liu, T.
- Neue Suche nach: Yang, Z.
- Neue Suche nach: Si, W. K.
- Neue Suche nach: Niu, C. C.
- Neue Suche nach: Zhao, C.
- Neue Suche nach: Zhang, X. L.
- Neue Suche nach: Pan, J.
- Neue Suche nach: Wu, W. R.
- Neue Suche nach: Li, Z. Q.
- Neue Suche nach: Liu, T.
- Neue Suche nach: Yang, Z.
- Neue Suche nach: Si, W. K.
In:
LEUKEMIA RESEARCH -OXFORD-
;
37
, 11
;
1532-1537
;
2013
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and @c-catenin inhibition
-
Beteiligte:Niu, C. C. ( Autor:in ) / Zhao, C. ( Autor:in ) / Zhang, X. L. ( Autor:in ) / Pan, J. ( Autor:in ) / Wu, W. R. ( Autor:in ) / Li, Z. Q. ( Autor:in ) / Liu, T. ( Autor:in ) / Yang, Z. ( Autor:in ) / Si, W. K. ( Autor:in )
-
Erschienen in:LEUKEMIA RESEARCH -OXFORD- ; 37, 11 ; 1532-1537
-
Verlag:
- Neue Suche nach: Elsevier Science B.V., Amsterdam.
-
Erscheinungsdatum:01.01.2013
-
Format / Umfang:6 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.99419
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 616.99419 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 37, Ausgabe 11
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1395
-
Striving to achieve safe, permanent treatment discontinuation in chronic myeloid leukemiaMauro, M. J. et al. | 2013
- 1404
-
Hematogones: An overviewChantepie, S. P. / Cornet, E. / Salaun, V. / Reman, O. et al. | 2013
- 1412
-
The role of SOX11 in mantle cell lymphomaLu, T. X. / Li, J. Y. / Xu, W. et al. | 2013
- 1420
-
Role of microRNA deregulation in the pathogenesis of diffuse large B-cell lymphoma (DLBCL)Mazan-Mamczarz, K. / Gartenhaus, R. B. et al. | 2013
- 1429
-
Struggling with myelofibrosis-associated anemiaGuglielmelli, P. / Vannucchi, A. M. et al. | 2013
- 1432
-
DNMT3A mutations in AML: A new prognostic factor?Schwarz, J. / Markova, J. et al. | 2013
- 1434
-
''It's effective therapy, stupid!''Ravandi, F. et al. | 2013
- 1436
-
The pros and cons of new prognostic eutos score for chronic myeloid leukemia patientsBreccia, M. / Alimena, G. et al. | 2013
- 1438
-
Unravelling survival pathways: The road to next-generation chronic myeloid leukaemia drugs?Deeren, D. et al. | 2013
- 1440
-
Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaDaver, N. / Shastri, A. / Kadia, T. / Quintas-Cardama, A. / Jabbour, E. / Konopleva, M. / O'Brien, S. / Pierce, S. / Zhou, L. / Cortes, J. et al. | 2013
- 1445
-
DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patientsShivarov, V. / Gueorguieva, R. / Stoimenov, A. / Tiu, R. et al. | 2013
- 1451
-
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapyLou, Y. / Suo, S. / Tong, H. / Ye, X. / Wang, Y. / Chen, Z. / Qian, W. / Meng, H. / Mai, W. / Huang, J. et al. | 2013
- 1457
-
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemiaTiribelli, M. / Bonifacio, M. / Calistri, E. / Binotto, G. / Maino, E. / Marin, L. / Guardalben, E. / Branca, A. / Gherlinzoni, F. / Semenzato, G. et al. | 2013
- 1461
-
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignanciesSampath, D. / Malik, A. / Plunkett, W. / Nowak, B. / Williams, B. / Burton, M. / Verstovsek, S. / Faderl, S. / Garcia-Manero, G. / List, A. F. et al. | 2013
- 1468
-
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of ageVigil, C. E. / Tan, W. / Deeb, G. / Sait, S. N. / Block, A. W. / Starostik, P. / Griffiths, E. A. / Thompson, J. E. / Greene, J. D. / Ford, L. A. et al. | 2013
- 1472
-
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcomeCherry, M. / Cardenas-Turanzas, M. / Pham, H. / Kantarjian, H. / Cortes, J. / Pierce, S. / Zhou, L. / Verstovsek, S. et al. | 2013
- 1477
-
Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemiaShimizu, H. / Saitoh, T. / Hatsumi, N. / Takada, S. / Handa, H. / Jimbo, T. / Sakura, T. / Miyawaki, S. / Nojima, Y. et al. | 2013
- 1482
-
Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromeGao, L. / Gong, Y. / Zhang, C. / Chen, X. H. / Zhang, X. et al. | 2013
- 1488
-
CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic riskPark, S. H. / Chi, H. S. / Cho, Y. U. / Jang, S. / Park, C. J. et al. | 2013
- 1495
-
Income and outcome in myelodysplastic syndrome: The prognostic impact of SES in a single-payer systemEngland, J. T. / Zhang, L. / Buckstein, R. / Lenis, M. / Li, C. / Earle, C. / Wells, R. A. et al. | 2013
- 1502
-
A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemiaHoward, D. S. / Liesveld, J. / Phillips, G. L. / Hayslip, J. / Weiss, H. / Jordan, C. T. / Guzman, M. L. et al. | 2013
- 1509
-
Increased prevalence of autoimmune phenomena in myelofibrosis: Relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patternsBarcellini, W. / Iurlo, A. / Radice, T. / Imperiali, F. G. / Zaninoni, A. / Fattizzo, B. / Guidotti, F. / Bianchi, P. / Fermo, E. / Consonni, D. et al. | 2013
- 1516
-
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabineLi, X. / Chang, C. / He, Q. / Xu, F. / Zhang, Q. / Wu, L. / Su, J. / Zhang, X. / Zhou, L. / Wu, D. et al. | 2013
- 1522
-
Recovery of natural killer cells and prognosis after cord blood transplantationYamamoto, W. / Ogusa, E. / Matsumoto, K. / Maruta, A. / Ishigatsubo, Y. / Kanamori, H. et al. | 2013
- 1527
-
Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patientsThyagarajan, B. / Arora, M. / Guan, W. / Barcelo, H. / Jackson, S. / Kumar, S. / Gertz, M. et al. | 2013
- 1532
-
Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and @c-catenin inhibitionNiu, C. C. / Zhao, C. / Zhang, X. L. / Pan, J. / Wu, W. R. / Li, Z. Q. / Liu, T. / Yang, Z. / Si, W. K. et al. | 2013
- 1538
-
Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndromePoloni, A. / Serrani, F. / Berardinelli, E. / Maurizi, G. / Mariani, M. / Costantini, B. / Trappolini, S. / Mancini, S. / Olivieri, A. / Leoni, P. et al. | 2013
- 1545
-
Pyothorax-associated lymphoma (PAL) with biclonal Epstein-Barr virus infection: Characterization of a novel PAL cell line with unique featuresTaniguchi, A. / Hashida, Y. / Nemoto, Y. / Taguchi, T. / Iwahara, Y. / Daibata, M. et al. | 2013
- 1551
-
Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8Hu, X. / Wei, H. / Xiang, L. / Chertov, O. / Wayne, A. S. / Bera, T. K. / Pastan, I. et al. | 2013
- 1557
-
The E3 ubiquitin ligase TRAF2 can contribute to TNF-@a resistance in FLT3-ITD-positive AML cellsSchnetzke, U. / Fischer, M. / Spies-Weisshart, B. / Zirm, E. / Hochhaus, A. / Muller, J. P. / Scholl, S. et al. | 2013
- 1565
-
Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cellsTanios, R. / Bekdash, A. / Kassab, E. / Stone, E. / Georgiou, G. / Frankel, A. E. / Abi-Habib, R. J. et al. | 2013
- 1572
-
Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1Pullarkat, S. T. / Pullarkat, V. / Lagoo, A. / Brynes, R. / Weiss, L. M. / Bedell, V. / Chen, W. / Huang, Q. / Gaal, K. / Weisenburger, D. D. et al. | 2013
- 1576
-
Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromesKefala, M. / Papageorgiou, S. G. / Kontos, C. K. / Economopoulou, P. / Tsanas, A. / Pappa, V. / Panayiotides, I. G. / Gorgoulis, V. G. / Patsouris, E. / Foukas, P. G. et al. | 2013
- 1583
-
CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatmentZhang, H. / Chang, G. / Wang, J. / Lin, Y. / Ma, L. / Pang, T. et al. | 2013
- 1592
-
Distinct sensitivity of CD8^+CD4^- and CD8^+CD4^+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse modelZhang, Y. / Hua, C. / Cheng, H. / Wang, W. / Hao, S. / Xu, J. / Wang, X. / Gao, Y. / Zhu, X. / Cheng, T. et al. | 2013